Nasdaq:IMNN
Imunon, Inc.
A clinical-stage biotech firm specializing in autoimmune and oncology therapeutics with zero current revenue and heavy reliance on capital raises.
Key Metrics
Investment Thesis
Bull Case
An aggressive investor might buy IMNN based on potential value creation if a single clinical trial succeeds, offering massive upside from a distressed valuation. The company's focus on high-value autoimmune targets could lead to significant licensing deals or commercialization partnerships that improve the financial outlook. Early entry allows investors to participate in the development of next-generation therapies before they face generic competition.
Bear Case
The stock is fundamentally unsustainable without immediate access to capital, given the massive retained earnings deficit and lack of revenue generation. Investors should avoid this asset due to the high probability of dilution from continuous equity fundraising in a bearish market environment. The current financial structure suggests a near-term risk of insolvency or acquisition at a distressed price if clinical milestones are not met quickly.
About Imunon, Inc.
Imunon, Inc. (IMNN) is a clinical-stage biotechnology company focused on developing novel therapeutics for autoimmune diseases and cancer. The company currently has no commercial revenue, relying entirely on equity financing to fund its extensive research and development pipeline. Its financial profile reflects a high-burn, early-stage entity with significant cash outflows dedicated to advancing proprietary immunotherapies.
Analysis
Management Discussion
Management is actively pursuing capital raises to sustain operations, evidenced by a $9.1 million inflow from share issuances in 2024 which partially offset an operating cash burn of nearly $19 million. The balance sheet shows minimal liquidity with only $5.9 million in cash and equivalents against total liabilities exceeding $5.5 million, indicating tight financial constraints. Despite these pressures, the company continues to invest heavily in R&D ($11.6M) and depreciation ($240k), signaling continued commitment to its scientific mission despite negative net income.
Industry Overview
The biotechnology industry is characterized by high failure rates, long development cycles, and significant capital requirements to bring new drugs to market. Companies in the autoimmune and oncology sectors face intense competition from established giants and smaller biotechs vying for funding from venture capitalists and public markets. Regulatory hurdles and clinical trial complexity make profitability elusive for most early-stage players until late-stage trials are successful.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $500.0K | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $500.0K | $0 | $0 |
| Operating Expenses | $25.4M | $21.0M | $19.1M |
| Operating Income | $-24.9M | $-21.0M | $-19.1M |
| R&D | $11.7M | $11.3M | $11.6M |
| G&A | $13.7M | $9.7M | $7.5M |
| Stock-Based Comp | $2.7M | $759.0K | $477.3K |
| D&A | $731.6K | $248.0K | $240.0K |
| Depreciation | $197.0K | $248.2K | $240.2K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $-12.5M | $235.1K | $512.2K |
| Interest Expense | $5.0M | $197.1K | — |
| Pre-Tax Income | $-37.5M | $-20.8M | $-18.6M |
| Income Tax | $-1.6M | $-1.3M | $0 |
| Continuing Ops | $-35.9M | $-19.5M | $-18.6M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-35.9M | $-19.5M | $-18.6M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-35.9M | $-19.5M | $-18.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $37.2M | $18.2M | $8.0M |
| Cash & Equivalents | $11.5M | $5.8M | $5.9M |
| Marketable Securities | $21.2M | $9.8M | — |
| Other Current Assets | $4.4M | $2.6M | $2.1M |
| Long-Term Assets | $6.8M | $3.7M | $1.7M |
| PP&E (Net) | $548.3K | $751.9K | $541.3K |
| Operating Leases | $155.9K | $1.6M | $1.1M |
| Other LT Assets | $6.1M | $1.3M | $50.0K |
| Total Assets | $44.0M | $21.9M | $9.7M |
| Current Liabilities | $10.0M | $7.4M | $4.8M |
| Accounts Payable | $3.6M | $3.5M | — |
| Current Leases | $230.7K | $485.4K | $452.4K |
| Other Current Liab | $1.4M | $0 | $1.3M |
| Long-Term Liabilities | $4.6M | $1.1M | $686.9K |
| LT Operating Leases | — | $1.1M | $686.9K |
| Other LT Liab | — | $0 | $0 |
| Total Liabilities | $14.6M | $8.5M | $5.5M |
| Shareholders' Equity | $29.3M | $13.4M | $4.2M |
| Paid-In Capital | $398.0M | $401.5M | $411.0M |
| Retained Earnings | $-368.7M | $-388.2M | $-406.8M |
| AOCI | $26.5K | $60.8K | — |
| Treasury Stock | $85.2K | $85.2K | $85.2K |
| Total L&E | $44.0M | $21.9M | $9.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-35.9M | $-19.5M | $-18.6M |
| Non-Cash Adjustments | $10.8M | $2.4M | $3.2M |
| Working Capital Changes | $2.0M | $-1.9M | $-3.5M |
| Cash from Operations | $-23.1M | $-19.0M | $-18.9M |
| Capital Expenditures | $267.8K | $451.8K | $29.5K |
| Cash from Investing | $8.3M | $11.0M | $9.8M |
| Cash from Financing | $6.7M | $-3.6M | $9.1M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-8.1M | $-11.7M | $34.2K |
| Beginning Cash | $25.6M | $17.5M | $5.8M |
| Ending Cash | $17.5M | $5.8M | $5.9M |
Frequently Asked Questions
How does Imunon, Inc. make money?
The company operates primarily through its R&D pipeline targeting unmet needs in autoimmune disorders and cancer, with no distinct commercial product lines generating revenue at this time. All financial activity is directed toward clinical trial execution, drug discovery, and partnership development rather than sales operations.
What are the main risks for IMNN?
The company faces extreme revenue risk as it currently generates no income and has a massive accumulated deficit of over $400 million, threatening long-term solvency. High cash burn rates combined with limited operating cash flow create severe dilution risks through frequent equity issuances to fund operations. Clinical trial failures for its pipeline assets could render the company's valuation moot without additional funding sources.
What is IMNN's competitive advantage?
Imunon leverages a proprietary platform technology designed to modulate the immune system for treating complex diseases like Type 1 diabetes and cancer. The company benefits from strategic collaborations that may reduce development costs and accelerate time-to-market for its asset portfolio. A highly skilled scientific leadership team provides deep expertise in navigating the stringent regulatory landscape of the FDA.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.